Trials / Completed
CompletedNCT00570635
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
A Phase 2 Study of XL820 in Subjects With Advanced Gastrointestinal Stromal Tumors Resistant to or Intolerant of Imatinib and/or Sunitinib
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the clinical benefit of the KIT inhibitor XL820 in subjects with advanced gastrointestinal stromal tumors (GIST) who are resistant to or intolerant of Imatinib and/or Sunitinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL820 | XL820 capsules administered orally as a single agent at a dose of 800 mg daily |
| DRUG | XL820 | XL820 capsules administered orally as a single agent at a dose of 300 mg twice daily |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2007-12-11
- Last updated
- 2013-06-07
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00570635. Inclusion in this directory is not an endorsement.